Organic compounds -- part of the class 532-570 series – Organic compounds – Nitrogen attached directly or indirectly to the purine ring...
Reexamination Certificate
2007-06-19
2007-06-19
Saeed, Kamal A. (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Nitrogen attached directly or indirectly to the purine ring...
C546S144000, C546S167000, C548S455000, C548S465000
Reexamination Certificate
active
10454561
ABSTRACT:
The present invention is directed to novel substituted pyrroline compounds useful as kinase or dual-kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase or dual-kinase mediated disorder.
REFERENCES:
patent: 5057614 (1991-10-01), Davis et al.
patent: 5624949 (1997-04-01), Heath, Jr. et al.
patent: 5721245 (1998-02-01), Davis et al.
patent: 6037475 (2000-03-01), Faul et al.
patent: 6479490 (2002-11-01), Gong et al.
patent: 6849643 (2005-02-01), Zhang
patent: 6987110 (2006-01-01), Zhang
patent: 7125878 (2006-10-01), Zhang
patent: 2004/0192718 (2004-09-01), Zhang
patent: 2004/0259928 (2004-12-01), Zhang
patent: 2005/0004201 (2005-01-01), Zhang
patent: 2005/0004202 (2005-01-01), Zhang
patent: 2006/0205762 (2006-09-01), Zhang
patent: 2006/0205763 (2006-09-01), Zhang
patent: 1057484 (2000-12-01), None
patent: 1120414 (2001-08-01), None
patent: WO 91/13071 (1991-09-01), None
patent: WO 9517182 (1995-06-01), None
patent: WO 9811102 (1998-03-01), None
patent: WO 00/06564 (2000-02-01), None
patent: WO 00/21927 (2000-04-01), None
patent: WO 02/10158 (2002-02-01), None
patent: WO 02/38561 (2002-05-01), None
patent: WO 0246183 (2002-06-01), None
PCT Search Report dated Oct. 8, 2003 for PCT/US03/17569.
Davis, P.D. et al.: “Inhibitors of Protein Kinase C1.2,3-Bisarytmaleimides” Journal of Medicinal Chemistry, American Chemical Society. Washington, D.C., U.S. vol. 35, No. 1, 1992, pp. 177-184.
Zhu G et al: “Synthesis of Quinolinly/Isoquinolinyl(a)pyrrolo(3,4-c) Carbazoles as Cyclin D1/CDK4 Inhibitors” Bioorganic & Medicinal Chemistry Letters, Oxford, GB, vol. 13, Apr. 1, 2003, pp. 1231-1235 XP002255246.
International J. Pharm, 1986, 33, 201-217.
J. Pharm. Sci., Jan. 1977, 66(1), p. 1.
P. Xia, et al., J. Clin. Invest., 1996, 98, 2018.
H. Ishii, et al., J. Mol. Med., 1998, 76, 21.
Inoguchi, et al., Proc. Natl. Acad. Sci. USA, 1992, 89, 11059-11065.
Bastyr III, E.J. and Lu, J., Diabetes, 1993, 42, (Suppl. 1) 97A.
Hsieh, et al., Proc. Natl. Acad. Sci USA, 1991, 88, 9315-9319.
Hsieh, et al., J. Biol. Chem., 1993, 268, 15118-15126.
Murray, et al., J. Biol. Chem, 1993, 268, 15847-15853.
Bilder, G.E., et al., J. Pharmacol. Exp. Ther., 1990, 252, 526-530.
Matsumoto, H. and Sasaki, Y., Biochem. Biophys. Res. Commun., 1989, 158, 105-109.
Yan, S-F, et al., J. Biol. Chem., 2000, 275, 16, 11921-11928.
Ren, S., et al., Am. J. Physiol., 2000, 278 (4, Pt. 1), E656-E-662.
Muid, R.E., et al., FEBS Lett., 1990, 293, 169-172.
Sonoki, H. et al., Kokyu-To Junkan, 1989, 37, 669-674.
Kobayashi, et al., Amer. Phys. Soc., 1994, H1214-H1220.
Toullec, D., et al., J. Biol. Chem., 1991, 266, 15771-15781.
Karasik, A., et al., J. Biol. Chem., 1990, 265, 10226-10231.
Chen, K.S., et al., Trans. Assoc. Am. Physicians, 1991, 104, 206-212.
Chin, J.E., et a., J. Biol. Chem., 1993, 268, 6338-6347.
Lee, T-S., et al., J. Clin. Invest., 1989, 83, 90-94.
Lee, T-S., et al., Proc. Natl. Acad. Sci. USA, 1989, 86, 5141-5145.
Craven, P.A. and Derubertis, F.R., J. Clin. Invest., 1989, 87, 1667-1675.
Wolf, B.A., et al., J. Clin. Invest., 1991, 87, 31-38.
Tesfamariam,B., et al., J. Clin. Invest., 1991, 87, 1643-1648.
Ishii, H., et al., Science, 1996, 272, 728-731.
X. Gu, et al., Circ. Res., 1994, 75, 926.
R. H. Strasser, et al., Circulation, 1996, 94, 1551.
H. Wakasaki, et al., Proc. Natl. Acad. Sci. USA, 1997, 94, 9320.
Twoemy, B., et al., Biochem. Biophys. Res. Commun., 1990, 171, 1087-1092.
Mulqueen, J.M., et al., Agents Actions, 1992, 37, 85-89.
Nechushtan, H., et al., Blood, Mar. 2000, 95, 5, 1752-1757.
Ren, S., et al., Am. J. Physiol., 2000, 278, (4, Pt. 1), E656-E-662.
Nagpala, P.G., et al., J. Cell Physiol., 1996, 2, 249-55.
Dekker, L.V., et al., Biochem. J., 2000, 347, 285-289.
Slater. M.J., et al., Biorg. & Med. Chem., 1999, 7, 1067-1074.
Rabbi, M.F., et al., Virology, Jun. 5, 1998, 245, 2, 257-69.
Leitges. M., et al., Science (Wash., D.C.), 1996, 273, 5276, 788-789.
Horn, F., et al., J. Invest. Dermatol., 1987, 88, 220-222.
Raynaud, F. and Evain-Brion, D., Br. J. Dermatol., 1991, 124, 542-546.
Hegemann, L., et al., Arch. Dermatol. Res., 1991, 283, 456-460.
Bollag, W.B. et al., J. Invest. Dermatol., 1993, 100, 240-246.
Rotenberg, S.A. and Weinstein, I.B., Biochem. Mol. Aspects Sel. Cancer, 1991, 1, 25-73.
Ahmad, et al., Molecular Pharmacology, 1993, 43, 858-862.
Meyer, T., et al., Int. J. Cancer, 1989, 43, 851-856.
Akinagaka, S., et al., Cancer Res., 1991, 51, 4888-4892.
Sauma, S., et al., Cell Growth Differ., 1996, 7, 5, 587-94.
Konig, A., et al., Blood, 1997, 90, 10, Suppl. 1 Pt. 2.
Danso, D., et al., Proc. Am. Assoc. Cancer Res., 1997, 38, 88 Meet., 92.
Harrington, E.O., et al., J. Biol. Chem., 1997, 272, 11, 7390-7397.
Begemamm, M., et al., Anticancer Res. (Greece), Jul.-Aug. 1998, 18, 4A, 2275-82.
Teicher, B.A., et al., Proc. Am. Assoc. Cancer Res., 1998, 39, 89 Meet., 384.
Teicher, B.A. et al., Clinical Cancer Research, Mar. 2001, 7, 634-640.
Huang, K.P., Trends Neurosci., 1989, 12, 425-432.
Shimohama, S., et al., Neurology, 1993, 43, 1407-1413.
Hara, H., et al., J. Cereb. Blood Flow Metab., 1990, 10, 646-653.
Shibata, S., et al., Brain Res., 1992, 594, 290-294.
Beldhuis, H.J.A., et al., Neuroscience, 1993, 55, 4, 965-73.
Miletic, V., et al., Neurosci. Lett., 2000, 288, 3, 199-202.
Chen, C., et al., Science (Wash, D.C.), 1997, 278, 5336, 279-283.
Embi, et al., Eur. J. Biochem, 1980, 107, 519-527.
Cross, et al., Biochemical Journal, 1994, 303, 21-26.
Villar-Palasi C. and Larner J., Biochim. Biophys. Acta, 1960, 39, 171-173.
Parker, P.J., et al., Eur J. Biochem, 1983, 130, 227-234.
Cohen, P., Biochem. Soc. Trans., 1993, 21, 555-567.
Srivastava, A.K. and Pandey S.K., Mol. and Cellular Biochem., 1998, 182, 135-141.
Chen, et al., Diabetes, 1994, 43, 1234-1241.
Eldar-Finkelman, et al., PNAS, 1996, 93, 10228-10233.
Eldar-Finkelman and Krebs, PNAS, 1997, 94, 9660-9664.
Eldar-Finkelman, et al., Diabetes, 1999, 48, 1662-1666.
Gat, et al., Cell, 1998, 95, 605-614.
Hoeflich, K.P., et al., Nature, 2000, 406, 86-90.
Pap and Cooper, J. Biol. Chem., 1998, 273, 19929-19932.
D'Mello, et al., Exp. Cell Res., 1994, 211, 332-338.
Nonaka and Chuang, Neuroreport, 1998, 9(9), 2081-2084.
Hong, J. et al., J. Biol. Chem. 1997, 272(40), 25326-32.
Ikeda, et al., EMBO J., 1998, 17, 1371-1384.
Eastman, Grosschedl, Curr. Opin. Cell Biol., 1999, 11, 233.
Cotter, D., et al., Neuroreport, 1998, 9, 1379-1383.
Lijam, N., et al., Cell, 1997, 90, 895-905.
Manji, et al., J. Clin. Psychiatry, 1990, 60, (Suppl 2) 27-39.
U.S. Appl. No. 11/528,092, filed Sep. 27, 2006, Zhang.
Conway Bruce
Demarest Keith
Hecker Leonard R.
Maryanoff Bruce E.
McComsey David F.
Janssen Pharmaceutica N.V.
Saeed Kamal A.
LandOfFree
Substituted pyrrolines as kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted pyrrolines as kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted pyrrolines as kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3823827